XGEN Venture, Sofinnova Partners, and CDP Venture Capital led a €83.5m Series A round in NanoPhoria.

XGEN Venture, an Italian alternative investment fund manager, Sofinnova Partners, a private equity firm, and CDP Venture Capital, a venture capital firm, led a €83.5m Series A round in NanoPhoria, a pre-clinical stage biotech company, with participation from Panakès Partners and European Innovation Council Fund. “NanoPhoria’s platform has the potential to redefine treatment paradigms in cardiovascular and other chronic diseases, which is why we are excited to invest in this company,” Henrijette Richter, Sofinnova Partners Managing Partner.